Chiome Bioscience
Tokyo · Founded 2005
About Chiome Bioscience
Chiome Bioscience was established in 2005 to commercialize the innovative ADLib® antibody generation technology invented at RIKEN. Since that time the Company has worked on research and development for this system, as well as initiatives for technology licensing. It focused mainly on joint research and contract research with the research arms of pharmaceutical companies and academia. Meanwhile, in 2011 the Company was listed on the Mothers market of the Tokyo Stock Exchange, and in 2015 it merged with LivTech which focused on drug discovery and development of therapeutic antibody for oncology, thus adding drug discovery function. In 2017 the Company went through reorganization of the management team, switching its strategy from platform development to drug discovery and development. At the same time it started setting up the clinical function which enables us to run a clinical study aiming of significant increase in corporate value.
Company Facts
- Founded: 2005
- Legal name: Chiome Bioscience Inc.
- Operating status: IPO
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Funding stage: IPO
- Last round: Undisclosed (May 2005)
- Website: chiome.co.jp
- Phone: +81 363-833-561
Social Profiles
Canonical: https://fsome.com/organization/chiome-bioscience-8296734 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.